Human papillomavirus DNA in sera of cervical cancer patients as tumor marker

2003 ◽  
Vol 202 (2) ◽  
pp. 231-239 ◽  
Author(s):  
Andreas Widschwendter ◽  
Anya Blassnig ◽  
Annemarie Wiedemair ◽  
Elisabeth Müller-Holzner ◽  
Hannes M Müller ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Papillomavirus Dna

scholarly journals Prognostic significance of negative conversion of high-risk Human Papillomavirus DNA after treatment in Cervical Cancer patients

2020 ◽  
Vol 11 (20) ◽  
pp. 5911-5917
Author(s):  
Qingqing Chen ◽  
Runjun Shi ◽  
Zhengcao Liu ◽  
Zhouhong Shi ◽  
Ke Gu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
High Risk ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Papillomavirus Dna ◽  
Negative Conversion

scholarly journals Human papillomavirus genotyping as a tool for cervical cancer prevention: from commercially available human papillomavirus DNA test to next-generation sequencing

2020 ◽  
Vol 6 (9) ◽  
pp. FSO603
Author(s):  
Tauana Christina Dias ◽  
Adhemar Longatto-Filho ◽  
Nathalia C Campanella
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cervical Cancer Prevention ◽  
Cancer Development ◽  
Cervical Carcinogenesis ◽  
Dna Test ◽  
First Time ◽  
Papillomavirus Dna ◽  
Principal Elements ◽  
Generation Sequencing

The biological importance of human papillomavirus (HPV) in the field of medicine – related to cervical carcinogenesis – has been extensively reported in the last decades. For the first time, a direct correlation between cause and effect to explain a cancer development was completely achieved in medical research. Consequently, the Nobel Prize was awarded to HZ Hausen in 2008 for his efforts to understand the effects of persistent infection of oncogenic types of HPV and malignancy transformation. The aim of the present review was to summarize the principal elements of HPV characteristics and their importance in oncology.

scholarly journals Human papillomavirus genotypes in Pacific Islander cervical cancer patients

2018 ◽  
Vol 24 ◽  
pp. 83-86
Author(s):  
T.M. Schisler ◽  
A.K. Bhavsar ◽  
B.P. Whitcomb ◽  
J.H. Freeman ◽  
M.A. Washington ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Patients ◽  
Pacific Islander

scholarly journals Prognostic implication of human papillomavirus types in cervical cancer patients: a systematic review and meta-analysis

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Yuanyuan Xu ◽  
Yichao Qiu ◽  
Shuang Yuan ◽  
Hongjing Wang
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Hpv 16 ◽  
Free Survival ◽  
American Society ◽  
Hpv 18

Abstract Background To estimate the prognostic relevance of human papillomavirus (HPV) 16 and HPV 18 in patients with cervical cancer. Method We searched PubMed, EMBASE, American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO), CNKI, and Wanfang databases to search primary articles illustrating the survival outcomes in cervical cancer patients with or without HPV 16/18 infection. A meta-analysis was conducted to generate a combined hazard ratio (HR) with 95% confidence intervals (CI) for progression-free survival (PFS), disease free survival (DFS) and overall survival (OS). Results A total of 13 studies were included. Our meta-analysis revealed that HPV 16 positive did not have any impact on OS (HR, 0.76; 95% CI = 0.37–1.54; P = 0.44). Cervical cancer patiensts infected with HPV 18 had worse OS (HR, 1.66; 95% CI = 1.28–2.17; P = 0.0001), DFS (HR, 2.10; 95% CI = 1.73–2.54; P < 0.0001) and worse PFS (HR, 2.97; 95% CI = 1.69–5.23; P = 0.00012) compared with those not infected with HPV 18. cervical cancer patiensts infected with HPV 18 had worse PFS compared with those infected with HPV 16 ((HR, 1.34; 95% CI = 1.06–1.70; P = 0.01). Conclusion Cervical cancer patients infected with HPV 18 had worse survival compared with cervical cancer patients with HPV 16 infection.

Prevalence, survival outcomes, and clinicopathologic factors associated with negative high risk human papillomavirus in surgical specimens of cervical cancer with pretreatment negative DNA genotype test

2019 ◽  
Vol 29 (1) ◽  
pp. 10-16
Author(s):  
Gun Oh Chong ◽  
Hyung Soo Han ◽  
Ji Young Park ◽  
Seon Duk Lee ◽  
Yoon Hee Lee ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Polymerase Chain Reaction ◽  
Human Papillomavirus ◽  
High Risk ◽  
Odds Ratio ◽  
Survival Outcomes ◽  
Chain Reaction ◽  
Genotype Test ◽  
Polymerase Chain ◽  
Papillomavirus Dna

ObjectiveThe aim of this study was to detect high risk human papillomavirus in cervical cancer with a pretreatment negative high risk human papillomavirus DNA genotype test and to evaluate clinicopathologic characteristics and survival outcomes according to high risk human papillomavirus status.MethodsWe investigated high risk human papillomavirus status in surgical specimens from 30 cases of cervical cancer using polymerase chain reaction. Polymerase chain reaction primers were set to detect the presence of the common L1 and E7 regions of human papillomavirus types 16, 18, 31, 33, 45, 52, and 58. We analyzed the following clinicopathologic parameters to evaluate their relationships with high risk human papillomavirus status: age, histology, stage, tumor size, invasion depth, lymphovascular invasion, and recurrent status.ResultsAmong 30 cases with a pretreatment negative DNA genotype test, high risk human papillomavirus was detected in 12 (40.0%), whereas 18 (60.0%) were negatives. Of 12 high risk human papillomavirus positive cases, 10 (33.3%) were positive for the L1 region, 6 (20.0%) of the 7 types were positive for the E7 region, and 4 (13.1%) were positive for both L1 and E7 regions. According to a multiple logistic regression model, tumor size (odds ratio 7.80; 95% confidence interval 1.476 to 41.216; P=0.0097) and stage (odds ratio 7.00; 95% confidence interval 1.293 to 37.910; P=0.0173) were associated with negative high risk human papillomavirus DNA status. Kaplan–Meier survival plots showed that negative high risk human papillomavirus status was associated with worse disease free survival in contrast with positive high risk human papillomavirus status (P=0.0392).ConclusionsNegative high risk human papillomavirus was found in 60% of cervical cancers with a pretreatment negative DNA genotype test. Moreover, the negative high risk human papillomavirus group was associated with worse survival outcome.

Sign in / Sign up

Export Citation Format

Share Document